Koers Bioblast Pharma Ltd Nasdaq
Aandelen
IL0011319527
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 30,48 mln. 28,32 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -16 mln. -14,87 mln. | Nettowinst (verlies) 2025 * | -12 mln. -11,15 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-1,88
x | K/w-verhouding 2025 * |
-2,95
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 80,79% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Oren Hershkovitz
CEO | Chief Executive Officer | 47 | 16-11-19 |
Dror Mevorach
FOU | Founder | 68 | 01-01-09 |
Director of Finance/CFO | 47 | 01-01-16 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Shai Novik
CHM | Chairman | 58 | 26-03-19 |
Avri Havron
BRD | Director/Board Member | 76 | 01-01-14 |
Brian Schwartz
BRD | Director/Board Member | 52 | 01-12-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+8,96% | 105 mld. | |
-1,43% | 104 mld. | |
+4,40% | 22,94 mld. | |
-12,15% | 22,34 mld. | |
-4,36% | 19,25 mld. | |
-39,98% | 17,08 mld. | |
-10,04% | 16,96 mld. | |
+38,61% | 12,63 mld. | |
+313,59% | 8,49 mld. |